Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab

Trial Details

NCT ID
NCT04434040
Phase
PHASE2
Sponsor
Dana-Farber Cancer Institute
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Atezolizumab
  • Sacituzumab govitecan
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Chicago, Illinois, United States|41.85003,-87.65005
  • New Lenox, Illinois, United States|41.51198,-87.96561
  • Orland Park, Illinois, United States|41.63031,-87.85394
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Pathologically confirmed residual invasive breast cancer, in the breast and/or lymph node(s), following neoadjuvant chemotherapy. In the absence of…
  • HER2 negative in primary tumor pre-treatment by local pathology assessed according to current ASCO/CAP guidelines:
  • In situ hybridization non-amplified (ratio of HER2 to CEP17 \< 2.0 or single probe average HER2 gene copy number \< 4 signals/cell), OR
  • Immunohistochemistry (IHC) 0 or IHC 1+.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →